Here we focused on GM-CSF-mediated JAK2 signaling [14] and explored the impact of JAKi (upadacitinib, baricitinib and tofacitinib), which are approved for RA treatment in Japan [15, 16]. Here, JAK2 is linked to rheumatoid arthritis.